Category

News

Meet our specialists – Frank de Bruijn

The PamStation is at the core of PamGene’s technology. This fully automated instrument is designed for processing PamChip microarrays to measure kinase activity and can be found at universities worldwide....
Read More

Jointly advancing mutation-independent treatment of inherited retinal diseases

transMed is an integrated training network funded by the European Union to train the next generation of scientists in translational medicine. The consortium focuses on bench-to-bedside development of treatments for...
Read More

Meet our specialists | Unraveling disease mechanisms

“My work at PamGene has always been data driven,” tells Rik de Wijn, data scientist and PamGene’s head of diagnostic assay services. De Wijn joined Pamgene in 2002 after completing...
Read More

PamGene and Sanquin announce extended collaboration to enhance development of PamGene’s predictive immunotherapy response tests

PamGene International B.V., a biomarker services company focused on the development of blood-based immunotherapy selection tests, and Sanquin, the not-for-profit blood services provider in the Netherlands, today announced the extension...
Read More

PamGene joins the 8th Drug Discovery Strategic Summit

Meet PamGene at the 8th Drug Discovery Strategic Summit in Amsterdam (November 4 and 5). Our colleagues Tushar Tomar and Martijn Dankers would be happy to discuss how PamGene’s kinase...
Read More

PamGene highlights new publications underscoring the importance of its kinome activity profiling technology, the basis of the IOpener® diagnostic test

Today, PamGene International B.V., an in-vitro diagnostics company focused on the development and commercialization of blood-based immunotherapy selection tests, highlights eight publications in international journals that have confirmed that kinase-activity...
Read More

PamGene, Novigenix and Radboud University Medical Center secure Eurostars funding to develop a multi-omic predictive immunotherapy response test for bladder cancer patients

PRECISE, a Dutch-Swiss consortium between PamGene International B.V., Novigenix SA and Radboud University Medical Center, has been awarded a Eurostars grant of up to €1 million to develop a novel...
Read More

Learning why patients display poor response to a therapy by looking at deregulated kinase signaling

Kinases have been running like a thread through Dr. Julhash Uddin Kazi’s career. They also played the lead part in the Lund University’s Associate Professor of Molecular Medicine’s recent Nature...
Read More

PamGene receives extended ISO 13485:2016 certification for its IOpener® immunotherapy selection test services

PamGene International B.V., an in-vitro diagnostics company focused on the development and commercialization of blood-based immunotherapy selection tests, today announced it has received extension of its ISO 13485:2016 certification. The...
Read More

PamGene shares experience on biomarker development and ICI therapy response prediction at Cancer Bioinformatics Symposium

The 1st Annual Cancer Bioinformatics Symposium at the University of Toledo College of Medicine and Life Sciences will take place February 5th. The full day, online event champions collaboration between...
Read More
1 2 3 4 5